Sacrosidase
As of the edition of 20 October 2026, Sacrosidase is an enzyme: marketed, first approved in 1998 (US); US protection ended in 2010.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1998
- Kind
- Enzyme
- Brand name
- Sucraid
- First approved
- 9 April 1998 (US)
- Approvals on record
- 3 in 1 region
- Holder of the most recent approval
- QOL Medical
- Registered trials
- 4, 3 stopped early
- Disease areas
- Digestive system
US protection
US protection ended in 2010.
US protection ended in 2010, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by QOL Medical. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 2 listings behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 2 | 1 | 0 | 1 |
| Phase 4 | 2 | 0 | 0 | 2 |
| All trials | 4 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| QOL Medical | Applicant and Lead sponsor of trials | 1998 to now |